Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

WeB: A Pilot Study of WEarables for Bladder Monitoring in People with Multiple Sclerosis
Multiple Sclerosis
S7 - Multiple Sclerosis: Special Populations and Non-MS CNS Neuroinflammatory Disease (5:06 PM-5:18 PM)
009

Bladder dysfunction (BD) affects many PwMS and other neurological conditions. Sequelae include inherent bother, life-threatening infections, and decreased quality of life. Remote monitoring of BD through wearables could reduce substantial existing accessibility barriers to monitoring BD progression and instituting timely treatment.

Report findings from a pilot study of bladder wearables in people with multiple sclerosis (PwMS)

Phase I, a “Wearables for the Bladder” kit was selected by stakeholders using a human-centered design. The highest scoring tool for initial evaluation was DFree (a small non-invasive ultrasound patch measuring bladder urine volume). Phase II (feasibility study), women with MS (progressive or relapsing) and BD were enrolled (target N=20). Activities included a clinical post-void residual (PVR), wearing DFree for at least 3-5 days/month over 12-weeks, and a 3-day bladder diary. From raw minute-level device data, two measures were generated: home PVR (dPVR) and urinary frequency (dFrequency). Participant qualitative feedback on daily use was captured.

Among 21 participants enrolled (13 completers, 6 on-study, 2 dropouts), mean age was 50 (SD8.0), median EDSS was 4.0. Device utilization was on-target: mean use was 14.1 days.  Bland-Altman agreement was good between PVR and dPVR, with no systematic bias. Similar agreement was noted using all available dPVR data vs. just first 7 days; but d-PVR further visualized day-to-day variability not appreciated using single clinic snapshots. The correlation between dFrequency (mean 7.4, SD 2.9) and diary-reported frequency was 0.81. Participant feedback showed excellent usability, usefulness and ease of use and highlighted utility of DFree data for BD self-management: planning activities outside the home, reducing leakage frequency, and motivating to seek further treatment.

This pilot study provides initial insights into feasibility, validity and clinical utility of wearables to assess, monitor and treat BD. Knowledge gained includes optimization of device usage, data cleaning into novel outcomes, and targets for behavioral change.

Authors/Disclosures
Valerie A. Block, DPTSc (University of California, San Francisco)
PRESENTER
Dr. Block has received personal compensation in the range of $0-$499 for serving as a Consultant for Otivio. The institution of Dr. Block has received research support from National MS Society.
Anne Suskind No disclosure on file
Chu-Yueh Guo, MD (UCSF Medical Center) Dr. Guo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.
Shane Poole (UCSF) No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham) Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio, Medday, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, TG Therapeutics.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics, AI therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics,Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, NHLBI (Protocol Review Committee), University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc.. Dr. Cutter has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NeurologyLive. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Roche Genentech. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Eli Lilly.